|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.
|
18438407 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis.
|
21838531 |
2012 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Depletion of CD151 in breast cancer cells resulted in an increased level of FGFR2.
|
30257985 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression microarray analysis did not show transcriptional enhancement of Wnt/beta-catenin target genes but instead showed a translational gene signature that also correlated with elevated FGFR1 and FGFR2 in human breast cancer data sets.
|
20501844 |
2010 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGF-10 and its receptors, FGFR1 and FGFR2, have been implicated in breast cancer susceptibility and progression, suggesting that fibroblast growth factor (FGF) signaling may be co-opted by breast cancer cells.
|
22665522 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fibroblast growth factor 1 (FGF1) and RNA binding protein fox-1 homolog 2 (RBFOX2), which are functionally related to FGFR2, may also associate with breast cancer risk.
|
23143756 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fifty-three studies with a total of 121,740 cases and 198,549 controls have examined the associations between 23 variants in intron 2 of FGFR2 and the breast cancer risk.
|
26728143 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Finally, an application to the Shanghai Breast Cancer Study showed that rare causal variants at the FGFR2 gene were detected by T REM and SKAT, but T REM produced more consistent results for different sets of rare and common variants.
|
24338936 |
2014 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, PDGFRβ and FGFR2-mediated pathways, identified as relevant in mediating this characteristic, potentially represent valid targets for a specific therapy of this breast cancer subgroup.
|
24747080 |
2014 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For the region containing FGFR2 (a known breast cancer gene) the largest χ(2) is obtained under composite likelihood with imputed genotypes (χ(2)(2) increases from 20.6 to 22.7), and compares with a single SNP-based χ(2)(2) of 19.9 after correction.
|
20959865 |
2011 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four SNPs mapped to 10q26.13/FGFR2 were associated with increased breast cancer risk via an additive model with per-allelic risks (95 % CI) of 1.26 (1.12-1.43) at rs1219648, 1.22 (1.07-1.38) at rs2981582, 1.21 (1.07-1.36) at rs2981579, and 1.18 (1.04-1.35) at rs11200014.
|
22965832 |
2012 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Gene amplification and protein overexpression of fibroblast growth factor receptor 2 (FGFR2) characterize the SUM-52 breast cancer cell line developed in our laboratory.
|
17133345 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in FGFR2, identified by rs1219648, may account for a substantial fraction of breast cancer in Arab (12%), Ashkenazi (15%), and Sephardi Jewish (22%) populations.
|
18483326 |
2008 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
|
25751625 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies five new breast cancer susceptibility loci.
|
20453838 |
2010 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies novel breast cancer susceptibility loci.
|
17529967 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies novel breast cancer susceptibility loci.
|
17529967 |
2007 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci.
|
27354352 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of breast cancer in the Japanese population.
|
24143190 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
|
27764800 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we review the role of fibroblast growth factor receptor signalling in breast cancer, from SNPs in FGFR2 that influence breast cancer risk and SNPs in FGFR4 that associate with breast cancer prognosis, and potential therapeutic targets such as receptor amplification and aberrant autocrine and paracrine ligand expression.
|
22731805 |
2012 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, we have undertaken an evaluation of a possible relationship between FGFR2/RSK2 interdependence and disease outcome in breast cancer (BCa) patients.
|
27476168 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer.
|
19497954 |
2009 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.
|
23544012 |
2013 |